Virtual | September 21-23, 2023
THURSDAY, SEPTEMBER 21, 2023
8:00 AM – 11:00 AM
SESSION I (PART 1): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
State of the Art and Future Directions in “Smart” Prostate Cancer Screening
11:00 AM – 1:30 PM
SESSION I (PART 2): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling
NCCN Guidelines for Early Detection of Prostate Cancer 2023
1:30 PM – 3:30 PM
LUNCH BREAK
3:30 PM – 6:00 PM
SESSION II (PART 1): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Panel on Multiomics for Prostate Cancer
FRIDAY, SEPTEMBER 22, 2023
8:00 AM – 11:20 AM
SESSION II (PART 2): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Gleason Grading – Time to Start Afresh?
Artificial Intelligence for Improving Diagnosis and Treatment
Molecular and Multi-Modality Imaging
Integration of Precision Diagnosis and Precision Treatment
11:20 AM – 1:00 PM
LUNCH BREAK
1:00 PM – 6:00 PM
SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease
Molecular and Multi-Modality Imaging and Theranostics
SATURDAY, SEPTEMBER 23, 2023
8:00 AM – 11:00 AM
SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
Focal Therapy – Ready for Prime Time
Fundamental Challenges
Changing Relationship between Active Surveillance and Focal Therapy
Patient Selection – Radiologic and Urologic Perspectives
Machine Learning for Improved Staging
Standardized MRI and Molecular Imaging Reporting
Bending the Curve of Treatment for Immediate Risk Disease
Image-Guided Laser Ablation
Patient Outcomes of Partial Gland Ablation
Combination of Prostate Ablation with Systemic Therapy
11:00 AM – 1:00 PM
LUNCH BREAK
1:00 PM – 2:30 PM
PANEL ON PRECISION CARE AND HEALTH DISPARITIES IN PROSTATE CANCER
2:30 PM – 4:10 PM
PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTIMODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT
4:10 PM – 4:30 PM
PRESENTATION OF WINNING ABSTRACTS
4:30 ADJOURN
.
8:15 am SESSION I (PART 1): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Moderators:
Peter Albers, MD, Professor and Chairman, Department of Urology and Medical Director, Comprehensive Cancer Center, University Hospital, Heinrich-Heine-University, Düsseldorf; Professor of Urology and Division Head, Personalized Early Detection of Prostate Cancer, German Cancer Research Center, Heidelberg, Germany; and Chairman, Scientific Congress Office, European Association of Urology
Sigrid Carlsson, MD, PHD, MPH, Assistant Attending Epidemiologist, Departments of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden
8:30 am Topic 1: State of the Art and Future Directions in “Smart” Prostate Cancer Screening
8:30 am Topic 1A: Year in Review: Emerging Data and Advances in Screening
Sigrid Carlsson, MD, PHD, MPH
8:40 am Q & A
8:42 am Topic 1B: Overview – Why We Need Organized Screening Programs
Hendrik Van Poppel, MD, European Association of Urology Policy Office Chairman, and Professor, Department of Urology, University Hospitals Leuven, Belgium
8:54 am Topic 1C: Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50)
Peter Albers, MD, Professor and Chairman, Department of Urology and Medical Director, Comprehensive Cancer Center, University Hospital, Heinrich-Heine-University, Düsseldorf; Professor of Urology and Division Head, Personalized Early Detection of Prostate Cancer, German Cancer Research Center, Heidelberg, Germany; and Chairman, Scientific Congress Office, European Association of Urology
9:04 am Q & A
9:08 am Topic 1D: PROFILE Study – Early Data on Targeted Screening for Prostate Cancer in Men of African and African Caribbean Ancestry
Jana McHugh, MB, BCh, BAO, Clinical Research Fellow, Institute of Cancer Research and Honorary Senior Registrar in Clinical Oncology, Royal Marsden Hospital, NHS Foundation Trust, London, United Kingdom
9:16 am Q & A
9:18 am Topic 1E: MRI-Based Prostate Cancer Screening in an Era of MCEDs
Mark Emberton, MD, Dean, Faculty of Medical Sciences, and Professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London; and Honorary Consultant Urologist, University College London Hospital, United Kingdom
9:28 am Q & A
9:30 am Topic 1F: Prostate Cancer Screening Practices in Europe
Monique Roobol, PhD, Professor of Decision Making in Urology and the Head of the Scientific Research Office, Department of Urology, Erasmus University Medical Centre, Cancer Institute, Rotterdam, The Netherlands
9:40 am Q & A
9:42 am Topic 1G: Update on IMPACT – Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers and Men with Lynch Syndrome
Ros Eeles, PhD, FRCP, FRCR, Professor of Oncogenetics, The Institute of Cancer Research, Royal Marsden Hospital, University of London; and Honorary Consultant in Cancer Genetics and Clinical Oncology, National Health Service (NHS) Foundation Trust, London, United Kingdom
9:52 am Q & A
9:54 am Topic 1H: Clinical Trial of STHLM3 and MRI
Tobias Nordstrom, MD, PhD, Associate Professor of Urology, Consultant Urologist, Danderyd Hospital, Karolinska Institute, Sweden
10:04 am Q & A
10:06 am – 10:36 am Panel Discussion: “Smart” Prostate Cancer Screening
10:36 am – 11:00 am COFFEE BREAK
11:00 am SESSION I (PART 2): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Moderators:
Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel
Clare M. C. Tempany, MD, BAO, BCh, Ferenc Jolesz MD Professor of Radiology Harvard Medical School; Vice-Chair, Radiology Research Brigham & Women’s Hospital; Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS Standardization
11:00 am Topic 2: Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling
11:00 am Topic 2A: Current and Emerging Molecular and Genetic Diagnostics
11:00 am Overview of Liquid Biomarkers
E. David Crawford, MD, Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Grand Rounds in Urology; and Prostate Cancer Series Editor, Oncology Journal
11:10 am Q & A
11:12 am Diagnostic and Prognostic Biomarkers for Prostate Cancer – Sponsored by MDxHealth
Ericka Bagi, BSN, RN, Senior Medical Science Liaison, MDxHealth
11:22 am – 11:34 am Panel Discussion: Molecular and Genetic Diagnostics
11:34 am Topic 2B: Current and Emerging Imaging Tools and Targeted Biopsies
11:34 am Micro-Ultrasound and MRI for Visualization of Prostate Cancer – Sponsored by Exact Imaging
Wayne Brisbane, MD, Assistant Professor or Urology, UCLA
11:46 am Q & A
11:48 am PI-RADS Standardization and Risk Assessment – Recent Advances and Future Plans
Clare M. C. Tempany, MB BAO BCh
11:58 am Q & A
12:00 pm Quality Improvement American College of Radiology Program in Prostate MRI
Andrei Purysko, MD, Clinical Assistant Professor of Radiology, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University; Staff, Section of Abdominal Imaging and Nuclear Radiology, Imaging Institute, Cleveland Clinic; Staff, Glickman Urological and Kidney Institute, Cleveland Clinic
.
12:10 pm Multi-modality (MRI+PET) Imaging for Improved Detection of csPC
David Margel, MD, PhD, Founder, Rabin Medical Center and BRCA clinic, Member, Early Detection Committee at the Cancer War Society
12:20 pm Q & A
12:24 pm Optimized 15 min Protocol with Deep Learning Acceleration for Prostate MRI – Are we there yet? Sponsored by Siemens Healthineers
.Mukesh Harisinghani, MD, Director of Abdominal MRI, Massachusetts General Hospital and Professor of Radiology, Harvard Medical School
12:34 pm Q & A
12:36 pm Optimizing MRI Targeted Biopsy – Including Endorectal Imaging for Tumor Localization and In–Bore Biopsy for Tissue Diagnosis
Fergus Coakley, MD, Professor and Chair of Diagnostic Radiology, School of Medicine, Oregon Health and Science University
12:46 pm Q & A
12:48 pm – 1:00 pm Panel Discussion: Imaging Modalities and Targeted Biopsies
3:30 pm SESSION II (PART 1): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Moderators:
Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF
.
Baris Turkbey, MD, Senior Clinician, Molecular Imaging, Center for Cancer Research, National Cancer Institute, National Institutes of Health
.
3:40 pm Topic 1: Panel on Multiomics of Prostate Cancer
3:40 pm Topic 1A: Emerging Data and Advances in Diagnostics of Prostate Cancer – Year in Review
Matthew Cooperberg, MD, MPH
3:50 pm Q & A
3:52 pm Topic 1B: Genomics – Prognostic and Predictive Markers
Ashley Ross, MD, PhD, Associate Professor of Urology, Feinberg School of Medicine, Northwestern Medicine, Northwestern Memorial Hospital
4:02 pm Q & A
4:04 pm Topic 1C: Integration of Imaging with Histology, Proteomics and Genomics
4:04 pm Urology Perspective
JanPhillip Radtke, MD, MBA, Consultant and Assistant Professor of Urology, Department of Urology, Essen University Medical Center and German Cancer Research Center
4:14 pm Q & A
4:16 pm MRI
Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA
.
.
4:26 pm Q & A
4:28 pm Molecular Imaging
Michael Hofman, MBBS, FRACP, FAANMS, FICIS, PET Modality Lead, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Peter MacCallum Department of Oncology, The University of Melbourne
.
4:38 pm Proteomics
Paul Boutros, PhD, MBA, Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA
4:48 pm Q & A
4:50 pm Pathology Overview
Thomas M. Wheeler, MD, Director of Surgical Pathology and Cytopathology, Sagis Diagnostics; Distinguished Emeritus Professor and Immediate Past Chair, Department of Pathology & Immunology, Baylor College of Medicine
5:00 pm Q & A
5:02 pm – 5:30 pm Panel Discussion: Multiomics
5:30 pm – 6:00 pm GENERAL DISCUSSION
8:00 am SESSION II (PART 2): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Moderators:
Carlos A. Buchpiguel, MD, PhD, Director of Molecular Imaging and Nuclear Medicine Division; and Full Professor, Department of Radiology and Oncology, São Paulo University School of Medicine, São Paulo -SP, Brazil
Andrei H. Iagaru, MD, Professor of Radiology – Nuclear Medicine Chief, Division of Nuclear Medicine and Molecular Imaging; and Co-Director, PET-MRI Research Program Stanford University
Raja B. Khauli, MD, Professor of Urology, American University of Beirut Medical Center, Beirut, Lebanon; and Professor of Surgery and Urology, Carle Health, College of Medicine, University of Illinois in Urbana-Champaign
Adam Kibel, MD, Elliott Carr Cutler Professor of Surgery, Harvard Medical School; Chief of Urology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute
Lalitha K. Shankar, MD, PhD, Chief, Clinical Trials Branch, Cancer Imaging Program, National Cancer Institute (NCI)
.
.
8:10 am Topic 2: Gleason Scoring Has Served Us Well for More than 50 Years, But It Is Time to Start Afresh
Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center
8:20 am Q & A
8:22 am Topic 3: Artificial Intelligence for Improving Prostate Cancer Diagnosis and Treatment
Martin Eklund, PhD, Professor of Epidemiology, Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Sweden
8:32 am Q & A
8:34 am Topic 4: Molecular and Multi-Modality Imaging for Visualization and Staging of the Initial and Recurrent Disease
8:34 am Topic 4A: MRI
Baris Turkbey, MD, Radiologist, National Cancer Institute, National Institutes of Health
8:44 am Q & A
8:46 am Topic 4B: Molecular and Multi-Modality Imaging – Predictive Value
Andrei H. Iagaru, MD
8:56 am Q & A
8:58 am Topic 4C: Construction and Multi-Center Validation of the Radiomics Model for Non-Invasive Identification of Active Surveillance Candidates
Liang Wang, MD, PhD, Professor, Attending Radiologist, Vice-Chairman for the Research and Development, Director of Urogenital Imaging, Department of Radiology, Beijing Friendship Hospital Capital Medical University, China
9:08 am Q & A
9:10 am Topic 4D: Emergent Applications of Prostate Cancer Mapping with Artificial Intelligence – Sponsored by Avenda Health
Alan Priester, PhD, Senior Data Scientist, Avenda Health
9:16 am Topic 4E: PSMA Imaging: PYLARIFY® (piflufolastat F 18) PET/CT Imaging – Sponsored by Lantheus
9:26 am – 10:00 am Panel Discussion
10:00 am – 10:30 am COFFEE BREAK
10:30 am Topic 5: Integration of Precision Diagnosis and Precision Treatment
10:30 am Topic 5A: Integrated Diagnostics (Radiogenomics) and Active Surveillance – Patient Selection and Monitoring
Sanoj Punnen, MD, Pap Corps Champions for Cancer Research Endowed Chair in Solid Tumor Research, Associate Professor and Vice Chair of Research, Department of Urology Co-Chair of Genitourinary Site Disease Group, Sylvester Comprehensive Cancer Center University of Miami, Miller School of Medicine
10:40 am Q & A
10:42 am Topic 5B: Selection and Outcomes of Image-Guided, Minimally- Invasive Treatment
Abhinav Sidana, MD, MPH, Associate Professor of Surgery, Director of Urologic Oncology, University of Cincinnati College of Medicine
10:52 am Q & A
10:54 am Topic 5C: Radiation Treatment
Daniel Y. Song, MD, Professor of Radiation Oncology and Molecular Radiation Sciences, and Co-Director, Prostate Cancer Multi-Disciplinary Clinic, Johns Hopkins University
11:04 am Q & A
11:06 am Panel Discussion: Integration of Precision Diagnosis and Treatment
11:20 am – 1:00 pm LUNCH BREAK
1:00 pm SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
Moderators:..
David Nanus, MD, Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine, and Director of the New York-Presbyterian Hospital – Weill Cornell Medicine Healthcare System Cancer Program
.
Steven Finkelstein, MD, DABR, FACRO, Florida Cancer Affiliates, the US Oncology Network; and Board of Chancellors, American College of Radiation Oncology
Fernando Maluf, MD, PhD, Director of Medical Oncology, Beneficencia Portuguesa; and Member, Steering Committee, Medical Oncology Center, Albert Einstein Hospital, São Paulo, Brasil
1:10 pm Topic 1: Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease
1:10 pm Topic 1A: International, Multi-Disciplinary Consensus on Treatment of Advanced Prostate Cancer
Silke Gillessen, MD, Director of the Oncology Institute of Southern Switzerland and Full Professor at USI Università della Svizzera italiana, Bellinzona, Ticino, Switzerland
1:20 pm Q & A
1:22 pm Topic 1B: Review of the New Standard in Treatment for Oligometastatic Disease: Androgen Deprivation Treatment (ADT), Chemotherapy, Androgen Receptors Inhibitors, and Androgen Synthesis Inhibitors
Marc Garnick, MD, Director of Cancer Community Services, Network Development, BIDMC, and Gorman Brothers Clinical Professor of Medicine at Harvard Medical School; and Special Advisor, Oncologic Drugs Advisory Committee of the FDA
1:30 pm Q & A
1:32 pm Topic 1C: Understanding Metastatic Castration Resistant Prostate Cancer – Sponsored by Pfizer
Shel Liang, PhD, US Medical Affairs, Pfizer Oncology
1:40 pm Topic 1D: Multi-Disciplinary Approach to Advanced Prostate Cancer Care
Kelvin A. Moses, MD, PhD, Associate Professor of Urology, Urologic Oncology Fellowship Director, and Director of Comprehensive Prostate Cancer Clinic, Vanderbilt University Medical Center, and Chair, NCCN Prostate Cancer Early Detection Guidelines Panel
1:50 pm Q & A
1:52 pm Topic 1E: Radiation Treatment and Its Integration with Precision Diagnostics
1:52 pm Radiation Therapy Planning Using Advanced Imaging – Pearls and Pitfalls – Sponsored by Blue Earth
Sean P. Collins MD, PhD, Professor of Radiation Medicine and Director, CyberKnife Prostate Program, Department of Radiation Medicine, Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center
2:04 pm Topic 1F: Emerging Advances in Radiation Treatment
Steven Finkelstein, MD, DABR, FACRO
2:18 pm Q & A
2:20 pm Topic 1G: Novel Targeted Treatment and Its Integration with Precision Diagnostics
Daniel P. Petrylak, MD, Professor of Medicine and Director of Genitourinary Oncology; and Co-Director of Signal Transduction Program, Yale University
2:30 pm Q & A
2:32 pm Topic 1H: Precision Diagnostics and Emerging Treatment Strategies
David Nanus, MD
2:42 pm Q & A
2:46 pm Topic 1I: Immunotherapy
Sandy Srinivas, MD, Medical Oncologist, Stanford Health Care; Professor of Medicine (Oncology) and Urology, Stanford University; and Vice Chair, NCCN Panel for Prostate Cancer Treatment
2:56 pm Q & A
2:58 pm Topic 1J: Sequencing of Treatment
Arnulf Stenzl, MD, Professor and Chairman, Department of Urology, University of Tuebingen, Germany; Secretary General Adjunct – European Association of Urology; and Member, European Cancer Organization (ECO) Board of Directors
3:08 pm Q & A
3:10 pm Panel Discussion: Standard and Emerging Treatment
3:20 pm – 3:40 pm COFFEE BREAK
3:40 pm Topic 2: Molecular and Multi-Modality Imaging and Theranostics
3:40 pm Topic 2A: Molecular Imaging for Staging and Treatment Planning, including Patient Eligibility and Selection for LuPSMA Therapy
Hossein Jadvar, MD, PhD, MPH, MBA, Professor of Radiology, Urology, and Biomedical Engineering, Division of Nuclear Medicine and Molecular Imaging Center, Keck School of Medicine & Viterbi School of Engineering, USC Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California
3:50 pm Q & A
3:52 pm Topic 2B: Theranostics
3:52 pm Overview and Interim Response Biomarkers – Radiologic Perspective
Louise Emmett, MD, Professor and Director, Department of Theranostics and Nuclear Medicine, St. Vincent Hospital; and Clinical Research Leader, Garvan Institute of Medical Research, Sydney, Australia
4:02 pm Medical Oncology Perspective
Philip Kantoff, MD, Past Chairman of Medicine, Memorial Sloan Kettering Cancer Center; and Jerome and Nancy Kohlberg Emeritus Chair in Medicine, Harvard Medical School
4:14 pm Panel Discussion: Molecular Imaging and Theranostics – Speakers, Moderators, and Guests
Harshad R. Kulkarni, MD, Nuclear Medicine/Theranostics Physician (Germany), Chief Medical Advisor, BAMF Health
Brandon Mancini, MD, MBA, Medical Director, BAMF Health
5:30 pm – 6:00 pm GENERAL DISCUSSION
8:00 am SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
Moderators:
David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York
Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine
Stephen Zappala, MD, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine
8:15 am Topic 1: Focal Therapy is Now Ready for Prime Time
Hashim Ahmed, MD, PhD, Professor and Chair, Division of Surgery, Department of Surgery and Cancer, Imperial College London; Honorary Consultant Urological Surgeon, Imperial Urology, Imperial College Healthcare, NHS Trust, United Kingdom
8:25 am Q & A
8:27 am Topic 2: Clinical and Genomic Implications of MRI Invisibility
Laurence Klotz, MD Professor of Surgery, University of
Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center; and Chair, World Urologic Oncology Federation
8:37 am Q & A
8:40 am Topic 3: Changing Relationship Between Active Surveillance and Focal Therapy
Mark Emberton, MD
8:50 am Q & A
8:52 am Topic 4: Patient Selection for Focal Therapy – Radiologic Perspective
John Feller, MD, Chief Medical Officer, HALO Diagnostics; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine
9:02 am Topic 5: Patient Selection for Prostate Cancer Focal Therapy – Urologic Perspective
Geoffrey Sonn, MD, Assistant Professor of Urology and Radiology, Stanford University School of Medicine
9:12 am Q & A
9:16 am Topic 6: Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-up – Creating Imaging-Based Short and Intermediate Outcomes
Daniel Margolis, MD, Associate Professor of Radiology, Director, Prostate MRI, and Chair, Weill Cornell Institutional Review Board, Weill Cornell Medical College, Cornell University
9:26 am Q & A
9:28 am Topic 7: Prostate Cancer Detection-Integrated Clinical Solution – Sponsored by Philips
Donald Baker, R.T.(R)(CT)(MR), Clinical Marketing Manager-MR, Philips Healthcare
9:38 am Q & A
9:40 am Topic 8: Machine Learning and Localized Prostate Cancer
Wayne Brisbane, MD
9:50 am Q & A
9:52 am – 10:30 am COFFEE BREAK
10:30 am Topic 9: Combination of Prostate Ablation with Systemic Therapy for Management of Prostate Cancer
10:42 am – 11:00 am Panel Discussion: Image-Guided Treatment
11:00 am – 1:00 pm LUNCH BREAK
1:00 pm PANEL ON PRECISION CARE AND HEALTH DISPARITIES IN PROSTATE CANCER
Moderators:
Adam B Murphy, MD, MBA, MSCI, Assistant Professor, Department of Urology & Preventive Medicine, Northwestern Medicine – Feinberg School of Medicine, Affiliate Member of Institute for Global Health and Center for Community Health
Quoc-Dien Trinh, MD, Co-Director, Dana-Farber/Brigham and Women’s Prostate Cancer Program; Director, Ambulatory Clinical Operations, Division of Urological Surgery; and Associate Professor of Surgery, Harvard Medical School
.
1:00 pm Community-Based and Patient-Centered Approaches to Addressing Racial Inequities in Prostate Cancer
Yaw Nyame, MD, MS, MBA, Assistant Professor, Department of Urology, University of Washington; Program Lead, Office of Community Outreach and Engagement and Affiliate Assistant Member, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center
1:10 pm Q & A
1:12 pm Risk Assessment in Black Men
Adam B Murphy, MD, MBA, MSCI
1:22 pm Utilization and Disparity Patterns Related to PC Markers
Michael Leapman, MD, MHS, Associate Professor of Urology, Clinical Program Leader, Prostate and Urologic Cancers Program, Yale Cancer Center
1:32 pm Q & A
1:34 pm Outreach Program to Address Racial Disparities in Prostate Cancer Care
Quoc-Dien Trinh, MD, MBA
1:44 pm Q & A
1:46 pm Panel Discussion: Health Disparities
2:10 pm – 2:30 pm COFFEE BREAK
2:30 pm PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI- MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT
Moderators:
Paul Boutros, PhD, MBA
Arnold C Cinman, MD, Partner, Tower Urology; and Attending Urologist, Cedars-Sinai Medical Center
Masoom Haider, MD, Professor of Radiology, University of Toronto; Senior Clinician Scientist, Lunenfeld Tanenbaum Research Institute; Director, Machine Learning and Radiomics Lab; and Director, Sinai Health System Research MRI, Canada
Michael H. Johnson, MD, Vice Chief of Urology, Washington University, St. Louis
2:30 pm Connected Care and Latest Developments in Prostate Cancer Management
Ilya Gipp, MD, PhD, Global Clinical Leader – Oncology, GE Healthcare
2:40 pm AI and MRI
Masoom Haider, MD
2:50 pm Q & A
2:52 pm Promise of Artificial Intelligence (AI) in Reducing Health Disparities in Prostate Cancer Surveillance, Diagnosis and Prognosis
Rakesh Shiradkar, PhD, Assistant Professor, Biomedical Engineering, Emory University. Member, Winship Cancer Institute
3:02 pm Q & A
3:04 pm Panel on Quantitative Imaging and its Role in Patient Management: Perspective from the Quantitative Imaging Network, National Cancer Institute
Amita Dave, PhD, Attending Physicist and Deputy Service Chief for Predictive Informatics, Director of Quantitative Imaging, Memorial Sloan Kettering Cancer Center; and Chair, Quantitative Imaging Network of the National Cancer Institute
Harini Veeraraghavan, PhD, Associate Attending Computer Scientist, Department of Medical Physics, Memorial Sloan Kettering Cancer Center
Lubomir Hadjiyski, PhD, Professor, Department of Radiology, University of Michigan
3:40 pm Current State of the Art and Vision for the Future
Paul Boutros, PhD, MBA
3:50 pm – 4:10 pm Panel Discussion: Bioinformatics, Artificial Intelligence and Machine Learning
4:10 pm – 4:30 pm Presentation of Winning Abstracts
Place #1: Development of Next Generation Extracellular Vesicle Based Urine Tests for Prostate Cancer: Sandra M. Gaston, PhD, Research Assistant Professor and Director, Molecular Biomarkers Analytic Laboratory, Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
Place #2: Artificial Intelligence-Based Cancer Mapping to Aid in Prostate Cancer Therapy: Sakina Mohammed Mota, Ph.D, Data Scientist, Avenda Health, Inc.
Place #3: Post-hoc Analysis of the LIGHTHOUSE and SPOTLIGHT Studies to Assess the Impact of Urinary Activity on Interpretation of 18F-flotufolastat PET/CT: Dr. Rick Hermsen, MD, Department of Nuclear Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
4:30 pm ADJOURN